- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Kidney pelvis.
Displaying page 1 of 2.
EudraCT Number: 2014-000669-39 | Sponsor Protocol Number: URU04 | Start Date*: 2014-06-13 | |||||||||||
Sponsor Name:Gregers Gautier Hermann | |||||||||||||
Full Title: Endoscopic treatment of neoplasia in the upper urinary tract and the value of fluorescence guided endoscopic follow up. | |||||||||||||
Medical condition: Urothelial tumors in the renal pelvis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002577-33 | Sponsor Protocol Number: ICR-CTSU/2011/10031 | Start Date*: 2012-01-04 | |||||||||||
Sponsor Name:Institute of Cancer Research | |||||||||||||
Full Title: A Phase III randomised trial of Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer | |||||||||||||
Medical condition: Upper urinary tract transitional cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003962-24 | Sponsor Protocol Number: VEN1 | Start Date*: 2008-10-15 | |||||||||||
Sponsor Name:Fredericia hospital | |||||||||||||
Full Title: visceral pain originating from the upper urinary tract - a randomised controlled trial on the effect of morphine and oxycodone in patients undergoing percutaneus nephrolithotomy (PCNL) | |||||||||||||
Medical condition: kidney stone | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004494-41 | Sponsor Protocol Number: CLIN2001UCM301 | Start Date*: 2021-06-11 | ||||||||||||||||
Sponsor Name:Steba Biotech, S.A. | ||||||||||||||||||
Full Title: Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer | ||||||||||||||||||
Medical condition: Low Grade Upper Tract Urothelial Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003946-18 | Sponsor Protocol Number: GDX-44-011 | Start Date*: 2019-05-03 | |||||||||||
Sponsor Name:GUERBET | |||||||||||||
Full Title: Efficacy and safety of gadopiclenol for body magnetic resonance imaging (MRI) | |||||||||||||
Medical condition: Patients presenting with know or suspected enhancing abnormality(ies) and/or lesion(s) in at least one body region among head & neck, thorax (including breast), abdomen (including liver, pancreas a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Completed) BG (Completed) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003328-35 | Sponsor Protocol Number: CHD062-13 | Start Date*: 2014-03-13 | |||||||||||
Sponsor Name:Centre Hospitalier Départemental Vendée | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020965-26 | Sponsor Protocol Number: VEG113387 | Start Date*: 2010-10-28 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nep... | ||||||||||||||||||
Medical condition: Renal Cell Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Completed) DE (Completed) DK (Completed) IE (Completed) CZ (Completed) ES (Completed) BE (Completed) GR (Completed) GB (Completed) AT (Completed) PL (Completed) HU (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-005087-25 | Sponsor Protocol Number: NeoPAN01-2013 | Start Date*: 2014-04-01 | |||||||||||
Sponsor Name:FUNDACION HOSPITAL DE MADRID | |||||||||||||
Full Title: Gemcitabine plus nab-paclitaxel versus folfirinox as neoadjuvant treatment in patients with potentially resectable pancreatic carcinoma. NeoPAN Study | |||||||||||||
Medical condition: Potentially resectable pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003138-33 | Sponsor Protocol Number: SPCG14 | Start Date*: 2008-12-12 | |||||||||||
Sponsor Name:Scandinavian Prostate Cancer Group (SPCG) | |||||||||||||
Full Title: A Randomized, Open Label, Phase III, Multicenter, 2-Arm Study of Androgen deprivation +/- Taxotere (Docetaxel) for Non metastatic Prostate Cancer Patients with a Rising PSA. | |||||||||||||
Medical condition: Patients with prostate cancer. The study will include two patient cohorts, which at inclusion has a similar risk for progression of the disease at 5 years, and risk of later prostate cancer death. ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) DK (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001881-27 | Sponsor Protocol Number: WO39210 | Start Date*: 2017-03-01 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developi... | |||||||||||||
Medical condition: Patients at high risk of Renal Cell Carcinoma (RCC) recurrence after nephrectomy and select patients with metastatic RCC recurrence who have undergone complete metastasectomy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) BE (Completed) PL (Completed) ES (Completed) IE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000147-98 | Sponsor Protocol Number: 20060159 | Start Date*: 2007-08-14 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Randomized, Double Blinded, Multi-Center Study 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metas... | |||||||||||||
Medical condition: A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metas... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003733-40 | Sponsor Protocol Number: CA183-002 | Start Date*: 2007-03-30 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gem... | |||||||||||||
Medical condition: Locally advanced or metastatic Transitional Cell Carcinoma (TCC) of the urothelium | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) ES (Completed) DK (Prematurely Ended) IT (Prematurely Ended) GR (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012696-97 | Sponsor Protocol Number: IGG-PNA IVU-01 | Start Date*: 2009-07-02 | |||||||||||
Sponsor Name:ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Management of children following acute pyelonefritis or recurrent urinary tract infection episodes and prevention of renal scarring: a prospective randomised controlled clinical trial. | |||||||||||||
Medical condition: URINARY TRACT INFECTION | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002474-39 | Sponsor Protocol Number: VBN-01 | Start Date*: 2018-01-17 | |||||||||||||||||||||||||||||||
Sponsor Name:Nykode Therapeutics AS | |||||||||||||||||||||||||||||||||
Full Title: An open-label first-in-human phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO or VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy... | |||||||||||||||||||||||||||||||||
Medical condition: Locally advanced or metastatic solid tumours including melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or SCCHN | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-006253-60 | Sponsor Protocol Number: EC07/90847 | Start Date*: 2008-04-11 | ||||||||||||||||||||||||||
Sponsor Name:MAR ESPINO HERNANDEZ | ||||||||||||||||||||||||||||
Full Title: Eficacia de la profilaxis antibiótica en dosis única nocturna frente al control clínico y tratamiento precoz de las infecciones urinarias para prevenir secuelas parenquimatosas y pielonefritis de r... | ||||||||||||||||||||||||||||
Medical condition: Demostrar que en los reflujos de alto grado (de III a V de la Clasificación Internacional del Reflujo) no hay menos incidencia de cicatrices renales ni de pielonefritis con el uso de la dosis única... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000049-30 | Sponsor Protocol Number: RITE-2 | Start Date*: 2017-07-26 |
Sponsor Name:Medical Enterprises Europe B.V | ||
Full Title: A multicenter, single-arm study evaluating the efficacy of Synergo radiofrequency-induced thermochemotherapy effect (RITE) with Mitomycin C( Synergo + MMC) in non-muscle invasive bladder cancer (NM... | ||
Medical condition: Non-Muscle-Invasive Bladder Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020620-22 | Sponsor Protocol Number: L00070 IN 213 PI | Start Date*: 2010-11-22 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Randomized phase II study assessing the combination of Vinflunine with Gemcitabine and Vinflunine with Carboplatin in patients ineligible to cisplatin with advanced or metastatic transitional cell ... | |||||||||||||
Medical condition: It concerns patients who cannot receive a cisplatin-based regimen as first line chemotherapy for an advanced or metastatic Transitional Cell Carcinoma of the Urothelium (TCCU), in particular those ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) AT (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001463-64 | Sponsor Protocol Number: CA183-001 | Start Date*: 2005-07-14 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium Revised Protocol #01, version 2.0 incorporating ... | ||
Medical condition: Advanced Cancer, IV, Nos | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) ES (Completed) SE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001441-12 | Sponsor Protocol Number: OP0595-5 | Start Date*: 2023-03-10 | ||||||||||||||||
Sponsor Name:Meiji Seika Pharma Co., Ltd. | ||||||||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Compli... | ||||||||||||||||||
Medical condition: Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: LT (Trial now transitioned) BG (Trial now transitioned) SK (Trial now transitioned) CZ (Trial now transitioned) LV (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005396-82 | Sponsor Protocol Number: L00070IN312P1 | Start Date*: 2015-09-03 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic urothelial carcinoma. | |||||||||||||
Medical condition: The trial concerns patients suffering from advanced or metastatic Transitional Cell Carcinoma of the Urothelium (TCCU) who are unfit for Cisplatin-containing first-line treatment due to reduced ren... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FR (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) GB (Completed) BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
